arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Beam Therapeutics Inc.

BEAM
$24.68 ▲ +0.31 (+1.27%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
31 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
32
Health
Poor
Bearish
auto_awesome

Analytical Summary

Beam Therapeutics Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.6B
Dividend Yield —
Revenue Growth -94.2% ↘
Op. Margin None
ROIC -8.6% ↘
FCF / Share $-0.66 ↗
Trailing P/E —
Price / Book 2.4x
FCF Yield —
Debt / Equity 0.09
info Valuation on last close. End-of-day price, Sep 24, 2026.

31-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$490.00K
↓ -94.2% —
Net Income Profit after all expenses
$-94.32M
↑ +12.9% —
Operating Margin Operating profit as % of sales
-337.8%
↓ -2109.7% 0th
FCF / Share Free cash flow per share
$-0.66
↑ +15.8% —
Long-Term Debt Long-term obligations
$100.26M
— +0.1% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
2
Returns ↑
37
Cash Quality ↑
95

bar_chart Data from SEC EDGAR XBRL filings

Synced 2 days ago 8 years · 31 quarters